Table 2.

Summary of Findings Table, PICO 1: “In Patients With an Initial CDI Episode, Should Fidaxomicin Be Used Rather Than Vancomycin?”

Anticipated Absolute Effects
Outcomes (Follow-up)No. of Participants (Studies)Certainty of the Evidence (GRADE)Relative Effect, RR (95% CI)Risk With VancomycinRisk Difference With Fidaxomicin (95% CI)
Sustained response of CDI (follow-up: 4 weeks after EOT)1673 (4 RCTs) [14,–,17]⊕⊕⊕◯ Moderatea,b1.16 (1.09 to 1.24)631 per 1000101 more per 1000 (57 more to 151 more)
CDI initial clinical curec (follow-up: 2 days after EOT)1673 (4 RCTs) [14,–,17]⊕⊕⊕◯ Moderatea,b,d1.00 (.96 to 1.04)856 per 10000 fewer per 1000 (34 fewer to 34 more)
Drug-related adverse events (follow-up: 4 to 12 weeks)1721 (4 RCTs) [14,–,17]⊕⊕◯◯ Low a,b,e1.02 (.76 to 1.36)95 per 10002 more per 1000 (23 fewer to 34 more)
All-cause mortality (follow-up: 4 to 12 weeks)1721 (4 RCTs) [14,–,17]⊕⊕⊕◯ Moderatea,b,e.90 (.66 to 1.23)87 per 10009 fewer per 1000 (30 fewer to 20 more)
Anticipated Absolute Effects
Outcomes (Follow-up)No. of Participants (Studies)Certainty of the Evidence (GRADE)Relative Effect, RR (95% CI)Risk With VancomycinRisk Difference With Fidaxomicin (95% CI)
Sustained response of CDI (follow-up: 4 weeks after EOT)1673 (4 RCTs) [14,–,17]⊕⊕⊕◯ Moderatea,b1.16 (1.09 to 1.24)631 per 1000101 more per 1000 (57 more to 151 more)
CDI initial clinical curec (follow-up: 2 days after EOT)1673 (4 RCTs) [14,–,17]⊕⊕⊕◯ Moderatea,b,d1.00 (.96 to 1.04)856 per 10000 fewer per 1000 (34 fewer to 34 more)
Drug-related adverse events (follow-up: 4 to 12 weeks)1721 (4 RCTs) [14,–,17]⊕⊕◯◯ Low a,b,e1.02 (.76 to 1.36)95 per 10002 more per 1000 (23 fewer to 34 more)
All-cause mortality (follow-up: 4 to 12 weeks)1721 (4 RCTs) [14,–,17]⊕⊕⊕◯ Moderatea,b,e.90 (.66 to 1.23)87 per 10009 fewer per 1000 (30 fewer to 20 more)

Abbreviations: CI, confidence interval; EOT, end of therapy; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; PICO, Patient/Population, Intervention/Indicator, Comparator/Control, Outcome; RCT, randomized controlled trial; RR, risk ratio; SOC, standard of care.

aDespite many subgroup analyses without prior stratification of the randomization reported in the study, Cornely et al (2012) [15] and Louie et al (2011) [14] were not considered at high risk of bias since the complete modified intention-to-treat population was used in our analysis. The Guery et al (2018) [16] study was at high risk of bias for self-reported outcomes due to potentially inadequate blinding. Guery et al (2018) and Mikamo et al (2018) [17] were considered at unclear risk of bias for possible attrition bias (significant loss to follow-up for the primary endpoint with imputation of missing data with failure for sustained clinical response).

bNot rated down for indirectness since patients with an initial CDI episode represented most patients included in the 4 reported (between 80% and 85%).

cInitial clinical cure was defined as no diarrhea for 2 consecutive days after completion of SOC antibiotic therapy administered for ≤16 days.

dOutcome determined as the primary endpoint in Cornely et al (2012) [15] and Louie et al (2011) [14] (while Mikamo et al (2018) [17] used global cure rate). Not rated down for imprecision, based on their prespecified margin of noninferiority of −10% (1-sided lower 97.5% CI).

eThe 95% CI includes the potential for both appreciable benefit as well as appreciable harm (ie, includes the null value) and few events reported do not meet the optimal information size.

Table 2.

Summary of Findings Table, PICO 1: “In Patients With an Initial CDI Episode, Should Fidaxomicin Be Used Rather Than Vancomycin?”

Anticipated Absolute Effects
Outcomes (Follow-up)No. of Participants (Studies)Certainty of the Evidence (GRADE)Relative Effect, RR (95% CI)Risk With VancomycinRisk Difference With Fidaxomicin (95% CI)
Sustained response of CDI (follow-up: 4 weeks after EOT)1673 (4 RCTs) [14,–,17]⊕⊕⊕◯ Moderatea,b1.16 (1.09 to 1.24)631 per 1000101 more per 1000 (57 more to 151 more)
CDI initial clinical curec (follow-up: 2 days after EOT)1673 (4 RCTs) [14,–,17]⊕⊕⊕◯ Moderatea,b,d1.00 (.96 to 1.04)856 per 10000 fewer per 1000 (34 fewer to 34 more)
Drug-related adverse events (follow-up: 4 to 12 weeks)1721 (4 RCTs) [14,–,17]⊕⊕◯◯ Low a,b,e1.02 (.76 to 1.36)95 per 10002 more per 1000 (23 fewer to 34 more)
All-cause mortality (follow-up: 4 to 12 weeks)1721 (4 RCTs) [14,–,17]⊕⊕⊕◯ Moderatea,b,e.90 (.66 to 1.23)87 per 10009 fewer per 1000 (30 fewer to 20 more)
Anticipated Absolute Effects
Outcomes (Follow-up)No. of Participants (Studies)Certainty of the Evidence (GRADE)Relative Effect, RR (95% CI)Risk With VancomycinRisk Difference With Fidaxomicin (95% CI)
Sustained response of CDI (follow-up: 4 weeks after EOT)1673 (4 RCTs) [14,–,17]⊕⊕⊕◯ Moderatea,b1.16 (1.09 to 1.24)631 per 1000101 more per 1000 (57 more to 151 more)
CDI initial clinical curec (follow-up: 2 days after EOT)1673 (4 RCTs) [14,–,17]⊕⊕⊕◯ Moderatea,b,d1.00 (.96 to 1.04)856 per 10000 fewer per 1000 (34 fewer to 34 more)
Drug-related adverse events (follow-up: 4 to 12 weeks)1721 (4 RCTs) [14,–,17]⊕⊕◯◯ Low a,b,e1.02 (.76 to 1.36)95 per 10002 more per 1000 (23 fewer to 34 more)
All-cause mortality (follow-up: 4 to 12 weeks)1721 (4 RCTs) [14,–,17]⊕⊕⊕◯ Moderatea,b,e.90 (.66 to 1.23)87 per 10009 fewer per 1000 (30 fewer to 20 more)

Abbreviations: CI, confidence interval; EOT, end of therapy; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; PICO, Patient/Population, Intervention/Indicator, Comparator/Control, Outcome; RCT, randomized controlled trial; RR, risk ratio; SOC, standard of care.

aDespite many subgroup analyses without prior stratification of the randomization reported in the study, Cornely et al (2012) [15] and Louie et al (2011) [14] were not considered at high risk of bias since the complete modified intention-to-treat population was used in our analysis. The Guery et al (2018) [16] study was at high risk of bias for self-reported outcomes due to potentially inadequate blinding. Guery et al (2018) and Mikamo et al (2018) [17] were considered at unclear risk of bias for possible attrition bias (significant loss to follow-up for the primary endpoint with imputation of missing data with failure for sustained clinical response).

bNot rated down for indirectness since patients with an initial CDI episode represented most patients included in the 4 reported (between 80% and 85%).

cInitial clinical cure was defined as no diarrhea for 2 consecutive days after completion of SOC antibiotic therapy administered for ≤16 days.

dOutcome determined as the primary endpoint in Cornely et al (2012) [15] and Louie et al (2011) [14] (while Mikamo et al (2018) [17] used global cure rate). Not rated down for imprecision, based on their prespecified margin of noninferiority of −10% (1-sided lower 97.5% CI).

eThe 95% CI includes the potential for both appreciable benefit as well as appreciable harm (ie, includes the null value) and few events reported do not meet the optimal information size.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close